Sino Biopharmaceutical (HK:1177) has released an update.
Sino Biopharmaceutical’s subsidiary, invoX Pharma, reported promising results from their ongoing phase 1 trial of FS222 in treating advanced solid tumors at the ASCO Annual Meeting. The novel antibody showcased significant anti-tumor effects and a manageable safety profile across various cancer types. The company plans to expedite FS222’s clinical development and leverage its proprietary antibody platform for further drug innovations.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
